10x Genomics inks license deal with Bio-Rad

By The Science Advisory Board staff writers

July 28, 2021 -- 10x Genomics and Bio-Rad Laboratories have settled their legal dispute and signed a global settlement and cross-license agreement.

According to the deal and for the life of the licensed patents, each company received a nonexclusive, worldwide, royalty-bearing license to develop products and services related to single-cell analysis, 10x Genomics said. Products related to spatial analysis and in situ analysis are excluded from the cross license as are digital polymerase chain reaction products from 10x Genomics.

The agreement settles all outstanding litigation and other proceedings between the two companies across all global jurisdictions. It also dismisses all infringement claims with prejudice, according to 10x Genomics. Both parties have agreed that each firm's patents are owned by each respective company.

10x Genomics launches FFPE Visium assay for research use
10x Genomics has launched its new Visium Spatial Gene Expression assay for formalin-fixed, paraffin-embedded (FFPE) samples, which gives researchers the...
Bio-Rad launches new StarBright dyes for flow cytometry
Bio-Rad Laboratories has unveiled three new StarBright dyes geared toward flow cytometry applications.
Bio-Rad reports 1st quarter gains
Bio-Rad Laboratories on Thursday announced financial results for its first quarter.
10x Genomics launches low-throughput gene expression kit
10x Genomics has launched its chromium single-cell gene expression low-throughput kit, a new offering designed to enable single cell analysis.
Bio-Rad's sales rise in Q4, full fiscal year
Bio-Rad Laboratories announced a jump in sales for its fourth quarter and full fiscal year due to increased demand for COVID-19 assays.

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter